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 Purpose 
Neonates are particularly challenging to treat. A novel patented drug delivery device 
containing a rapidly disintegrating tablet held within a modified nipple shield (NSDS) was 
designed to deliver medication to infants during breastfeeding. However concerns exist 
around dermatological nipple tolerability with no pharmaceutical safety assessment guidance 
to study local tissue tolerance of the nipple and the areola. 
This is the first Slug Mucosal Irritation (SMI) study to evaluate irritancy potential of GRAS 
excipients commonly used to manufacture rapidly disintegrating immediate release solid oral 
dosage form 
Methods 
Zinc sulphate selected as the antidiarrheal model drug that reduces infant mortality,  was 
blended with functional excipients at traditional levels [microcrystalline cellulose, sodium 
starch glycolate, croscarmellose sodium, magnesium stearate]. Slugs were exposed to blends 
slurried in human breast milk to assess their stinging, itching or burning potential, using 
objective values such as mucus production to categorize irritation potency  
Results 
Presently an in vivo assay, previously validated for prediction of ocular and nasal irritation, 
was used as an alternative to vertebrate models to anticipate the potential maternal 
dermatological tolerability issues to NSDS tablet components. The excipients did not elicit 
irritancy. However, mild irritancy was observed when zinc sulphate was present in blends. 
Conclusion 
These promising good tolerability results support the continued investigation of these 
excipients within NSDS rapidly disintegrating tablet formulations. Topical local tolerance 
effects being almost entirely limited to irritation, the slug assay potentially adds to the existing 
preformulation toolbox, and may sit in between the in vitro and existing in vivo assays. 
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ABBREVIATIONS  
API: Active Pharmaceutical Ingredient  
BAC: Benzalkonium Chloride 
CP: Contact Period 
GRAS: Generally Recognised as Safe 
HIV: Human Immunodeficiency Virus 
HLTV: Human T-lymphotropic Virus  
HBM: Human Breast Milk 
MP: Mucus Production 
NC: Negative Control 
NSDS: Nipple Shield Delivery System 
PC: Positive Control 
REC: Research Ethics Committee 
PBS: Phosphate Buffered Saline 
SIB: Stinging, Itching or Burning 
SMI: Slug Mucosal Irritation  
 INTRODUCTION 
Identifying the paediatric drug product technology gap 
The development of age appropriate medicines which deliver an active 
pharmaceutical ingredient (API) to children at the required rate and extent is a 
complex process.  Neonates are a particularly challenging sub-population to address 
for formulation scientists due to issues including dysphagia, taste aversion, and the 
need for frequent dose modifications. (1)  
Liquid formulations have been typically the dosage forms of choice for paediatric 
drug administration, but are often not practical in developing countries because of 
high cost, lack of access to refrigeration, contamination issues and limited shelf life. 
(2 - 4) They may also be unpalatable and contain undesirable or unsafe 
preservatives and solvents. (5) Solid oral dosage forms for infants are often scaled 
down from adult doses, and there is currently a debate on the limitations of clinical 
work performed to demonstrate suitability of the dose to the infant. (6, 7) Dispersible 
tablets can also be used, but require clean sources of water for reconstitution. They 
also require administration devices for which the volume of reconstituted suspension 
is calculated based upon body weight, body surface area or age, depending on the 
therapeutic index of the drug. However there is currently a WHO recommendation if 
not push for solid oral dosage forms to maximise drug product stability, particularly in 
developing countries. (8)  
A major contributor to this unacceptable statistic is diarrhoeal disease, the second 
leading cause of mortality in this age group, being responsible for 760,000 deaths 
yearly. (9) A significant proportion of the 1.7 billion annual cases of diarrhoeal 
disease reported globally could be prevented through ready access to clean drinking 
water alongside better sanitation and hygiene, both of which also limit the utility of 
medicines designed to be administered post reconstitution in drinking water.   
 
A potential solution to the paediatric drug product technology gap in neonates 
As a child friendly administration vehicle, milk has gained legitimacy and research 
continues to demonstrate its multiple benefits as a potential solubilizing, 
gastroprotective and taste masking agent. (10, 11) 
A novel “Nipple Shield Delivery System” (NSDS) has been proposed as a means to 
address some of these challenges, with preliminary proof-of-concept in vitro simulation 
studies and non-clinical user-acceptability studies conducted in the past five years. 
(12 - 16)   
This thin disposable device (Figure 1), in one format, could be adapted from an existing 
nipple shield breastfeeding aid to contain a fast dispersible or rapidly disintegrating 
tablet, and placed over the mother's breast just before infant feeding (12). When the 
human breast milk (HBM) passes through the device it releases an API to the infant 
via the milk. Based on patient need, a wide-range of APIs could be delivered to infants 
using the NSDS, such as antibiotics, antivirals, antimalarials, vitamins, nutrients, and 
probiotics. The APIs, which are stored in a dry form prior to reconstitution in HBM 
during administration, could therefore have longer shelf lives than other dosage forms. 
If further proven to be safe, effective and not interfere with the breastfeeding process 
(13-16), the NSDS has the potential to compliment dispersible tablet use in 
environments where infants breastfeed exclusively and remove many of the issues 
which can cause contamination of reconstituted drugs delivered to infants in 
resource-limited countries. More than 5.9 million children under 5 years of age died 
in 2015.  Many of these could have been prevented with access to appropriate forms 
of simple and affordable medicines and corresponding hygienic administration 
methods. (17)  
Zinc supplements, containing zinc sulphate have been shown to reduce the duration 
of diarrhoea episodes by 25% and are also associated with a 30% reduction in stool 
volume (9).  Zinc supplements are available in developing countries but require cup, 
bottle, or spoon delivery of the reconstituted suspension, limiting breastfeeding infant 
acceptability. Zinc sulphate, for which concentrations in HBM have not been 
conclusively shown to be impacted by maternal supplementation (18), constitutes 
therefore a relevant and important API to be delivered directly to neonates in an age 
appropriate manner.  
One safety consideration raised and addressed in this work, is the potential maternal 
tolerability of a modified NSDS. Specifically assessment of dermatological impacts due 
to potential irritancy of a concentrated suspension/slurry of APIs or excipients in HBM 
on the mother’s nipples is required. There is no pharmaceutical safety assessment 
guidance to study the local tissue tolerance of the nipple and the areola. The primary 
dermal irritation is the test rabbit screening procedure. The concept of the three Rs 
(refinement, reduction and replacement of laboratory animals) strongly stimulates the 
development of alternative testing methods, such as in vitro methods and the use of 
“lower” organisms as test species (e.g. invertebrates, plants and microorganisms). 
Presently the SMI assay was identified and explored as an in vivo assessment tool for 
this novel application. It was initially developed at the Laboratory of Pharmaceutical 
Technology at the University of Ghent to predict the mucosal irritation potency of 
pharmaceutical formulations and ingredients. (19, 20) The premise of the test is that 
slugs that are placed on an irritating substance will produce mucus. Tissue damage 
can be induced which results in the release of proteins and enzymes from the mucosal 
surface. Topical local tolerance effects being almost entirely limited to irritation, several 
studies have shown that the SMI assay is a useful tool for evaluating the local 
tolerance of pharmaceutical formulations and ingredients. (20-27) A classification 
prediction model that distinguishes between irritation (mucus production) and tissue 
damage (release of proteins and enzymes) has been developed. The SMI study is 
proposed more acceptable and ethical in terms of the principles of reduction, 
refinement and replacement, compared to previous tests such as the Draize test (23), 
an invasive procedure which involves applying relatively large volumes (0.5 mL or 0.5 
grams of a test substance to the eye or skin of a restrained, conscious mammal 
(usually a rabbit) and recording its effects. The SMI assay is a simple yet efficient way, 
to assess mucosal tissue irritation without using large numbers of vertebrates such as 
mice, rabbits or non-human primates or using more complex reconstructed human 
epidermis 3D skin models.  
The SMI assay complements existing predictive assays which are used in early 
pharmaceutical development and even has the potential to be used instead of the 
Draize test. Indeed, the relevance of the SMI assay to reliably predict nasal irritation, 
stinging and burning sensations has been demonstrated in a clinical trial using several 
Over the Counter (OTC) liquid nasal formulations, isotonic, and hypertonic saline. (29) 
It has also been shown that an increased mucus production with exposure to diluted 
shampoos was related with an increased incidence of stinging and burning sensations 
in the human eye irritation test. (30) The objective values obtained by means of the 
predictive SMI model for the mucus production, stinging, itching, or burning potential 
of the test blends can be estimated according to four categories (none, mild, moderate 
and severe). The limits for degree of discomfort on nasal and ocular mucosal surfaces 
are summarized in Table 1 (29, 30)  
The purpose of the present study was to attempt to predict topical irritation namely the 
stinging, itching or burning potential of a range of GRAS powder blends on the human 
nipple, some of which contain the model compound zinc sulphate, used in the 
treatment of diarrheal disease to support the development of a rapidly disintegrating 
tablet. 
 
MATERIALS AND METHODS 
Methods 
Slugs 
The parental slugs of Arion lusitanicus were collected in local gardens along Ghent 
and Aalter (Belgium) and bred in an acclimatized room at 18 - 20 °C. Test slugs were 
housed in plastic containers and fed with lettuce, cucumber, carrots, and commercial 
dog food. Slugs weighing between 3 and 6 g were isolated from the cultures two days 
before the start of an experiment. The body wall was inspected carefully for evidence 
of macroscopic injuries. Only slugs with clear tubercles and with a foot surface that 
showed no evidence of injuries were used for testing purposes. The slugs were placed 
in a plastic box lined with paper towel moistened with phosphate buffered saline (PBS) 
(0.01 M phosphate buffer, 0.0027 M potassium chloride, and 0.137 M sodium chloride) 
(Sigma Aldrich, St. Louis, MO, USA) at pH 7.4 and were kept at 18 – 20 °C. Daily, the 
body wall of the slugs was wetted with 300 µl PBS using a micropipette.  
Human breast milk 
Anonymised HBM samples were obtained from approximately 20 healthy donors from 
the Queen Charlotte's and Chelsea Hospital Milk Bank (Imperial College Healthcare 
NHS Trust). The donors had all consented for their milk to be used for research as it 
was not able to be used for donation. They were screened for HIV 1 and 2, HTLV I 
and II, hepatitis B and C, and syphilis, and ethical approval for use was obtained from 
the University of Cambridge (Cambridge Human Biology Research Ethics Committee 
(REC), University of Cambridge (REC number HBREC.2012.01). Milk from 10 donors 
was pooled for the experiment, half of which was centrifuged at 5411 g 
(5500 RPM) using a Sigma 3 –16 PK centrifuge (Sigma–Zentrifugen, Osterode, 
Germany) for 15 min. A fat layer obtained at the top of the flask was then carefully 
removed using a curved face spatula, and the remaining milk was pooled into a single 
flask. This fat layer, fat-free milk layer and the milk not centrifuged were then combined 
in this study to achieve a standardised fat content of 4.6 % wt.  Samples were then 
placed in 50 mL centrifuge tubes and stored at −80 °C to be used thawed prior making 
the slurries.   
Test slurries  
The following materials were sourced for the manufacture of blends A - I: zinc sulphate 
monohydrate (Sigma, Sigma-Aldrich, Dorset, UK); lactose monohydrate (direct 
compression grade, DFE Pharma Goch, Germany); sodium starch glycolate 
(Explotab, Mendell GmbH Volklingen, Germany); sodium croscarmellose (FMC 
Biopolymer, Girvan, UK); microcrystalline cellulose (MCC) (Avicel PH102, FMC 
Biopolymer, UK); magnesium stearate (Sigma-Aldrich, Dorset, UK); crospovidone 
(Polypasdone XL, Ashland, UK) and sodium stearyl fumarate (Alubra PG-100, FMC 
Biopolymer, UK). 
The following 330 mg blends, corresponding to the composition of one NSDS tablet 
containing 20 mg elemental zinc (6% w/w) based on blend A and I, detailed in Table 
2, were prepared by hand filling the individual components in to 6.5 mL glass 
scintillation vials followed by blending in a Turbula mixer at 44 rpm for 5 minutes.  
Blend A was comprised of a mixture of zinc sulphate and lactose (filler or bulking 
agent) in combination with functional excipients at levels commonly used in the 
formulation design of a rapidly disintegrating immediate release solid oral dosage 
form, namely:  microcrystalline cellulose (compression aid), sodium starch glycolate 
(disintegrant), croscarmellose sodium (disintegrant) and magnesium stearate 
(lubricant).  The composition of the blends E, F, G and H were chosen based on 
variations of the lead platform formulation (A) to comprise lactose and each of the 
functional excipients in blend A individually. An alternative disintegrant (crospovidone, 
blend B) and lubricant (sodium stearyl fumarate, blend C) were also evaluated.  Blends 
D and I acted as controls for zinc sulphate, and comprised lactose with all of the 
functional excipients and zinc sulphate respectively.  The blends were reconstituted 
into an homogenous slurry with the aid of vortex mixing until visually suspended, using 
1 mL HBM.  This volume was chosen to mimic a scenario where burst release of the 
API and excipients occurred, thus yielding potentially a worst case concentration for 
the compounds. The final slurries were designed to represent the most concentrated 
suspension that would be in contact with the mother’s nipple assuming near-instant 
disintegration of the tablet during breastfeeding. 
 
Methods 
The SMI assay 
Before a test was considered valid, the following criteria was met: the negative control 
(PBS) generated a total mucus production less than 5.5% of initial body weight to be 
classified as causing no stinging, itching, or burning; the positive control (1 w/v% 
benzalkonium chloride (BAC) (Sigma Aldrich, St. Louis, MO, USA)) in PBS generated 
a total mucus production above 17.5% of initial body weight to be classified as causing 
severe stinging, itching, and burning.  
The stinging, itching, or burning (SIB) potency of the test items and the negative and 
positive controls were evaluated by placing 3 slugs per treatment group 3 times a day 
on 100 µl of test slurry in a Petri dish. After each 15-min contact period (CP) the slugs 
were transferred for 60 min into a fresh Petri dish on paper towel moistened with 1 ml 
PBS to prevent desiccation. After the third CP the slugs were placed in a Petri dish on 
a membrane filter (cellulose acetate 0.45 µm, 90 mm diameter, Sartorius AG, 
Goettingen, Germany) moistened with 2 ml PBS until the next day. The overview of 
the test procedure is illustrated in figure 2. 
The amount of mucus produced during each contact period was measured by 
weighing the Petri dishes with the test item before and after each 15 minute CP. The 
mucus production was expressed as the % of the body weight. The slugs were 
weighed before and after each 15 minute CP and 24 hours after the first CP. The total 
mucus was calculated for each slug and then the mean per treatment group was 
calculated.  
Based on the endpoints of the SMI assay the stinging, itching, or burning potency of 
the test item(s), as defined in Table 1, was estimated using a classification prediction 
model. Mortality was documented for slugs exposed to each of the sample slurries, 
including the controls and HBM 24 hours after the third CP. 
 
RESULTS AND DISCUSSION 
The primary aim of this research was to evaluate the potential of commonly used tablet 
excipients and zinc sulphate used as an antidiarrheal model compound to cause 
irritation of the human nipple through extrapolation of the SMI assay. This utilizes the 
terrestrial slug Arion lusitanicus. The body wall of the slugs is layered and has a 
mucosal surface. The outer single-layered columnar epithelium contains cells with cilia 
and micro-villi.  Mucus secreting cells cover the subepithelial connective tissue. This 
micro-anatomy is similar to that of the lactiferous ducts of the mother’s nipple which 
are lined by a columnar epithelium supported by myoepithelial cells. Hence the SMI 
was hypothesized to be a potential predictive model for nipple irritancy during drug 
administration via the NSDS.  It was assumed that the results of this study would 
represent a worst case assessment for irritation, since ocular/nasal surfaces are more 
sensitive than skin. 
The average amount of mucus produced during each 15 minute CP and total MP is 
presented in Table 3, Figure 3.  
According to the classification prediction model of the SMI test, the negative control 
(PBS) did not induce reactions in the slugs (total MP < 3 - 5.5%). The positive control 
on the other hand (BAC 1% w/v) induced, as expected, a high mucus production during 
each contact period (total MP ≥ 17.5%) resulting in a classification corresponding to 
severe stinging, itching, and burning (SIB) reactions. The acceptance criteria were met 
and the experiment was considered valid. Graphical summaries of the data are 
presented in Figures 3 and 4. 
The total mucus production values for the reconstituted blends are bracketed by the 
positive and negative controls.  Slugs treated with HBM did not produce an increased 
amount of mucus compared to the negative control. Similarly the blends that did not 
contain zinc sulphate did not increase mucus to production to a level at which it could 
be classified as “mildly irritant” (Table 1), with the exception of blend H containing 
lactose and magnesium stearate, which only just exceeded by 0.1% the limit for “no 
irritation” as classified using the ocular classification only (Table 1 and Table 2). The 
total MP for HBM is only slightly negative, and it is therefore concluded that HBM was 
tolerated very well, resulting in a classification as not causing discomfort. The negative 
MP been induced (< -0.7%) may have also resulted in tissue damage, but this was not 
the case. 
Slugs treated with blends B, C, D, E, F, and G produced only a slightly increased 
amount of mucus during each contact period, compared to the negative control.  All 
placebo blends resulted in a total MP < 3 and 5.5%, corresponding with the 
classification “no SIB reactions”, suggesting acceptable tolerability. For all placebo 
blends the first contact induced the highest MP, but was much lower during the second 
and third CP.  The slightly negative mucus production that was observed for the 
negative control in the third CP was hypothesised to be due to the fact that the slugs 
produced only a minimal amount of mucus during each contact period and also that 
only a minimal amount of the test substance remains on the body wall of the slugs.  
Slugs treated with blends A and I, both containing the API zinc sulphate at a 
concentration of approximately 6% w/w, produced a higher amount of mucus during 
each CP in comparison with the negative control and all other blends tested. For blend 
A, the total MP also increased for the first two CPs; in the third CP it was lower than 
during the first CP. For blend I, MP was comparable during the first and second CPs, 
but increased substantially during the third contact period. This is however within the 
accepted limits. Similar reactions were observed in other experiments, where there is 
a certain tolerance for the first two CPs, and then an overreaction in the third CP. 
Although it can be interesting to look at the results of the three CPs separately, it is 
the total MP over the three CPs together that is used for the classification, as there 
can be quite some variability in the slugs’ reactions. Both blends induced a total MP 
between 10% and 17.5% and were therefore classified as causing moderate SIB 
reactions.   
With an n of 3 for each of the reconstituted slurries, considered alongside formulation 
(e.g. suspension homogeneity, which was not evaluated) and in vivo variability, it is 
not possible to assign statistical similarities or differences between the formulations in 
terms of mucus production, with a large degree of confidence.  However, the data 
suggests that the zinc sulphate is the major contributing factor to mucosal irritancy, 
and that the lack of response to the GRAS excipients evaluated promotes a large 
formulation design space.  It is to be noted that the concentrations tested represent a 
higher concentration than would be expected to be released using the NSDS, since it 
would likely take more than 1 mL of HBM to disintegrate a tablet during use. (12) 
Therefore, zinc sulfate may not cause as much irritancy as implied by this worst case 
study. 
No mortality was observed immediately following the three CPs, however 24 hours 
after the final CP, two out of three slugs had died in the cohort exposed to the positive 
controls as well as formulations A and I (both containing zinc sulphate).  The observed 
mortality in the slugs exposed to the positive control, was not surprising. Slugs treated 
with benzalkonium chloride using a similar protocol (30 min exposure to irritant each 
day for 5 days), often indicate tissue damage after the first contact period. (20, 21) 
This damage accumulates over time, inducing mortality of the slugs. In the current 
study, damage also occurred after exposure to benzalkonium chloride, although this 
was not quantified using microscopy, resulting in the observed mortality. 
Further, zinc salts (including sulphate) have been previously demonstrated to be highly 
toxic to freshwater fish and invertebrates and metal sulphates have been incorporated 
into proprietary slug and snail control products. (31) Exposure to elemental zinc in food 
(albeit at much higher concentrations) has been shown to have negative 
developmental impact on slugs. (32, 33)  
The relationship between API chemical structure and the endpoints mortality and MP, 
has previously been studied for the antimicrobial agent, benzalkonium chloride, and it 
was concluded that the activity and toxicity of different analogues depend on the alkyl 
chain length of the bactericidal molecule. (21) The slug mortality and increase in MP 
of the slugs exposed to slurries containing zinc sulphate appears to be due to the API 
and possibly related to its chemical structure; further investigations around API 
structure / SMI assay activity may help to better validate the model for different 
applications.  While the SMI data generated in this study suggest a possibility of local 
irritation on the human skin, the dermatological impact may be less than implied with 
this relatively non-invasive testing method, when nasal and ocular classification scales 
are used, as these are likely to be more sensitive than human skin. 
Further validation of the model is required to build an in vivo / in vivo correlation 
between the SMI model and irritancy of the breastfeeding nipple during administration 
of a rapidly disintegrating immediate release tablet via the NSDS. Such a correlation 
would be a useful pre-formulation tool to assess risk during early formulation 
development.  Additional opportunities to improve the predictiveness of the model for 
the selection of APIs for use with the NSDS include gaining a better understanding of 
similarities and differences of the histology of the breastfeeding nipple and the slug 
mucosa, considering species other than Arion lusitanicus for the assay, and 
essentially, optimising exposure time of the slugs to the concentrated slurries to 
correlate to an average breast feed.  Since the average HBM mass delivered per feed 
is estimated to be 50-80g of milk over a 7 to 10 minute period, the study of the tablet 
components at lower concentrations, correlating to slower release from the NSDS 
could be tested for irritancy potential. (34-36) 
 
CONCLUSIONS  
This was the first SMI study to be conducted evaluating excipients used in the 
manufacture of solid oral dosage forms, slurried in HBM. The existing SMI model has 
indicated a potential for local dermatological irritation when zinc sulphate at a 
potentially worst case concentration is delivered via the NSDS, with further 
investigation warranted. Mild irritation is suggested by the change in MP, and body 
weight of the slugs exposed to slurries of lactose and functional GRAS excipients that 
are used to induce rapid release of API from solid oral dosage forms. This implies 
these excipients could be used within functional levels as part of a flexible formulation 
design space that could facilitate the incorporation of a wide range of non-irritant APIs, 
with different physicochemical properties, into tablets for use with the NSDS. This 
could potentially broaden the utility of this novel drug delivery platform for the clinical 
treatment of neonates. 
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Fig. 1. A) Illustration of the Nipple shield delivery system (NSDS) design. B) NSDS 
prototype (11) 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Overview of the slug mucosal irritation (SMI) assay test procedure 
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Figure 3.  Total % MP of slurried tablet blends A to I [PBS: negative control; BAC1% 
positive control; HBM: human breast milk, * contains Zinc] 
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Fig. 4. Mean slug body weights as a function of time 
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 Table I. Cut-off values of Total Mean Mucus Production (%) for classification of 
ocular and nasal mucosal discomfort with the slug mucosal irritation (SMI) assay: 
(24, 25) 
Degree of discomfort 
Total Mean Mucus Production (%) 
Nasal Ocular 
None < 5.5% < 3% 
Mild ≥ 5.5 – < 10% ≥ 3 – < 8% 
Moderate ≥ 10 – <17.5% ≥ 8 – < 15% 
Severe ≥ 17.5% ≥ 15% 
 
 
 Table II.  Blends (total 330mg) for reconstitution in HBM (1ml) as slurries for SMI evaluation  
 Blend 
Ingredient 
(A) (B) (C) (D) (E) (F) (G) (H) (I) 
Zinc sulphate 54.9        54.9 
Direct compression lactose 222.3 297.0 325.0 277.2 320.1 323.4 297.0 326.7 275.1 
Sodium Starch Glycolate 9.9   9.9 9.9     
Crosscarmellose sodium 6.6   6.6  6.6    
Microcrystalline cellulose 33.0   33.0   33.0   
Magnesium stearate 3.3   3.3    3.3  
Crospovidone   33.0        
Sodium stearyl fumarate   5.0       
 Table III.   Amount of mucus produced during each 15 minute CP and total amount 
of mucus produced  
Formulation MP CP11 MP CP21 MP CP31 Total MP1 SIB 
Category2 
  (%) (%) (%) (%) 
NC - PBS 0.2 ± 0.1 0.2 ± 0.5 -0.3 ± 0.1 0.2 ± 0.3 No 
PC – BAC 1% w/v 5.7 ± 0.6 7.1 ± 2.2 7.7 ± 1.5 20.4 ± 4.3 Severe 
A* 3.9 ± 1.1 6.0 ± 1.4 2.6 ± 1.4 12.5 ± 1.5 Moderate 
B 0.8 ± 0.1 0.5 ± 0.4 0.6 ± 0.3 1.9 ± 0.5 No 
C 1.4 ± 0.4 0.7 ± 0.4 0.6 ± 0.3 2.6 ± 0.3 No 
D 0.9 ± 1.5 0.5 ± 0.5 0.4 ± 0.1 1.9 ± 1.9 No 
E 1.4 ± 1.2 0.3 ± 1.3 0.8 ± 0.4 2.5 ± 1.4 No 
F 1.2 ± 0.0 0.8 ± 0.3 0.5 ± 0.7 2.4 ± 0.8 No 
G 1.5 ± 0.6 0.0 ± 0.6 0.9 ± 0.9 2.4 ± 0.8 No 
H 1.6 ± 0.7 0.5 ± 0.3 0.9 ± 0.3 3.1 ± 1.3 No 
I* 3.3 ± 0.2 3.3 ± 0.7 4.7 ± 0.6 11.3 ± 1.0 Moderate 
J – HBM 0.0 ± 1.0 -0.2 ± 0.3 -0.5 ± 0.7 -0.7 ± 1.9 No 
1Mean ± SD, n = 3; 2 SIB (see table 1) NC: negative control; PC: positive control; HBM: 
human breast milk; * contains Zinc 
